Dietary glycemic index, glycemic load and cancer risk: a meta-analysis of prospective cohort studies

Author(s):  
Tingting Long ◽  
Ke Liu ◽  
Jieyi Long ◽  
Jiaoyuan Li ◽  
Liming Cheng
2019 ◽  
Vol 110 (4) ◽  
pp. 921-937 ◽  
Author(s):  
Farnaz Shahdadian ◽  
Parvane Saneei ◽  
Alireza Milajerdi ◽  
Ahmad Esmaillzadeh

ABSTRACT Background Previous findings on the association of dietary glycemic index (GI) and glycemic load (GL) with mortality are conflicting. Objectives The aim of this study was to summarize earlier findings on the association between dietary GI and GL and the risk of cardiovascular disease (CVD) and all-cause mortality. Methods A comprehensive literature search was performed of electronic databases, including MEDLINE (PubMed), Scopus, ISI Web of Science, EMBASE, and Google scholar, up to September 2018. Prospective cohort studies that reported GI and GL as the exposure and all-cause or CVD mortality as the outcome were included in the analysis. The random-effects model was used to estimate pooled RR and 95% CIs of all-cause and CVD mortality. Results Eighteen cohort studies with a total of 251,497 participants, reporting 14,774 cases of all-cause mortality and 3658 cases of CVD mortality, were included in the present analysis. No significant association was found between dietary GI and all-cause mortality (RR: 1.07; 95% CI: 0.96, 1.19) and CVD mortality (RR: 1.02; 95% CI: 0.87, 1.20). In addition, dietary GL was not associated with all-cause mortality (RR: 1.08; 95% CI: 0.93, 1.27) or CVD mortality (RR: 1.07; 95% CI: 0.92, 1.25). However, the highest dietary GI, in comparison to the lowest one, significantly increased the risk of all-cause mortality in women (RR: 1.17; 95% CI: 1.02, 1.35). No evidence for a nonlinear association between dietary GI or GL and all-cause and CVD mortality was found (P > 0.05). Conclusions This meta-analysis of prospective cohort studies showed no significant association between either dietary GI or GL and all-cause and CVD mortality in men, but a positive association of GI with all-cause mortality in women.


PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e74723 ◽  
Author(s):  
Yan Lu ◽  
Nong Tian ◽  
Jie Yin ◽  
Yuhua Shi ◽  
Zhenping Huang

2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Clara Bodelon ◽  
Srikant Ambatipudi ◽  
Pierre-Antoine Dugué ◽  
Annelie Johansson ◽  
Joshua N. Sampson ◽  
...  

Abstract Background Environmental and genetic factors play an important role in the etiology of breast cancer. Several small blood-based DNA methylation studies have reported risk associations with methylation at individual CpGs and average methylation levels; however, these findings require validation in larger prospective cohort studies. To investigate the role of blood DNA methylation on breast cancer risk, we conducted a meta-analysis of four prospective cohort studies, including a total of 1663 incident cases and 1885 controls, the largest study of blood DNA methylation and breast cancer risk to date. Methods We assessed associations with methylation at 365,145 CpGs present in the HumanMethylation450 (HM450K) Beadchip, after excluding CpGs that did not pass quality controls in all studies. Each of the four cohorts estimated odds ratios (ORs) and 95% confidence intervals (CI) for the association between each individual CpG and breast cancer risk. In addition, each study assessed the association between average methylation measures and breast cancer risk, adjusted and unadjusted for cell-type composition. Study-specific ORs were combined using fixed-effect meta-analysis with inverse variance weights. Stratified analyses were conducted by age at diagnosis (< 50, ≥ 50), estrogen receptor (ER) status (+/−), and time since blood collection (< 5, 5–10, > 10 years). The false discovery rate (q value) was used to account for multiple testing. Results The average age at blood draw ranged from 52.2 to 62.2 years across the four cohorts. Median follow-up time ranged from 6.6 to 8.4 years. The methylation measured at individual CpGs was not associated with breast cancer risk (q value > 0.59). In addition, higher average methylation level was not associated with risk of breast cancer (OR = 0.94, 95% CI = 0.85, 1.05; P = 0.26; P for study heterogeneity = 0.86). We found no evidence of modification of this association by age at diagnosis (P = 0.17), ER status (P = 0.88), time since blood collection (P = 0.98), or CpG location (P = 0.98). Conclusions Our data indicate that DNA methylation measured in the blood prior to breast cancer diagnosis in predominantly postmenopausal women is unlikely to be associated with substantial breast cancer risk on the HM450K array. Larger studies or with greater methylation coverage are needed to determine if associations exist between blood DNA methylation and breast cancer risk.


Oncotarget ◽  
2018 ◽  
Vol 9 (29) ◽  
pp. 20807-20815 ◽  
Author(s):  
Massimiliano Berretta ◽  
Agnieszka Micek ◽  
Alessandra Lafranconi ◽  
Sabrina Rossetti ◽  
Raffaele Di Francia ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document